SCHEMBL20964733

SCHEMBL20964733

Cc1cccc(N2CCN(C(=O)c3ccccc3SCc3c(C)noc3C)CC2)c1C

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.75
LMNA P02545 4/20 0.75
TSHR P16473 3/20 0.75
ALDH1A1 P00352 2/20 0.75
AR P10275 9/20 0.66
MAPT P10636 2/20 0.66
HTT P42858 2/20 0.66
CYP1A2 P05177 1/20 0.66
CYP3A4 P08684 1/20 0.66
CYP2C9 P11712 1/20 0.66
MAPK1 P28482 1/20 0.66
CYP2C19 P33261 1/20 0.66
STAT3 P40763 1/20 0.66
NPC1 O15118 2/20 0.54
L3MBTL1 Q9Y468 2/20 0.50
KDM4E B2RXH2 1/20 0.50
GLA P06280 1/20 0.50
GAA P10253 1/20 0.50
USP2 O75604 1/20 0.50
PKM P14618 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20964719 0.89 SMN1; SMN2 (0.77) SMN1; SMN2LMNATSHRALDH1A1AR
SCHEMBL20964944 0.89 TSHR (0.77) SMN1; SMN2LMNATSHRALDH1A1AR
SCHEMBL20964616 0.86 ALDH1A1 (0.73) SMN1; SMN2LMNATSHRALDH1A1AR
SCHEMBL19745442 0.85 LMNA (1.00) SMN1; SMN2LMNATSHRALDH1A1AR
SCHEMBL20964644 0.85 SMN1; SMN2 (0.71) SMN1; SMN2LMNATSHRALDH1A1AR
SCHEMBL20964683 0.84 LMNA (0.53) SMN1; SMN2LMNATSHRALDH1A1AR
SCHEMBL20964690 0.84 ALDH1A1 (0.79) SMN1; SMN2LMNATSHRALDH1A1AR
SCHEMBL20964680 0.83 LMNA (0.82) SMN1; SMN2LMNATSHRALDH1A1MAPT
SCHEMBL20964645 0.83 LMNA (0.82) SMN1; SMN2LMNATSHRALDH1A1AR
SCHEMBL20964654 0.82 ALDH1A1 (0.76) SMN1; SMN2LMNATSHRALDH1A1AR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10851096-B2 Aryl and heteroaryl amides for use as anti-proliferative, anti-thrombotic, and anti-viral agents RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2020-12-01 US disclosed
US-20190127361-A1 Therapeutic Compounds RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2019-05-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190127361-A1 Therapeutic Compounds SDHA, SLC10A1, SERPINC1 SMN1; SMN2 263/4885LMNA 1413/4885TSHR 3423/4885
US-10851096-B2 Aryl and heteroaryl amides for use as anti-proliferative, anti-thrombotic, and anti-viral agents SERPINC1, F12, RPL35 SMN1; SMN2 2477/4885LMNA 897/4885TSHR 2794/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.